Compare Dyne Therapeutics Inc. Common Stock (DYN) vs General Mills, Inc. (GIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs General Mills, Inc. — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while General Mills, Inc. trades at $32.48 (market cap $17.02B). The key difference: General Mills, Inc. is far larger — about 6× Dyne Therapeutics Inc. Common Stock's market cap, and General Mills, Inc. pays a 7.67% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and General Mills, Inc. for 107 Days on average.
| DYN | GIS | |
|---|---|---|
Market Cap | $2.86B | $17.02B |
Volume | 3,341,579 | 7,979,067 |
Sector | Health | Consumer Staples |
52-Week High | $26.78 | $49.18 |
52-Week Low | $14.60 | $31.67 |
Typical Hold Time | 0 Days | 107 Days |
Enterprise Value | $2.18B | $30.20B |
Dividend Yield | — | 7.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
General Mills (GIS) trades at $32.11, down 1.8% on the day, reflecting recent pressure from a Q4 2025 earnings miss and a projected net loss for 2026. The stock shows a bearish technical trend, with key support at $32. Despite a low P/E of 9.23, profitability metrics like a negative ROE of -10.55% and a forecasted negative net income margin for 2026 highlight significant challenges. Recent news includes a CEO transition and a reaffirmed $0.61 quarterly dividend, but investor sentiment remains cautious amid declining revenues and margin pressures.
The outlook for GIS is clouded by execution risks in its turnaround strategy and macroeconomic headwinds. The high dividend yield offers income appeal, but the potential for a dividend cut and sustained earnings weakness presents substantial risk. Analyst consensus is predominantly Hold, with a $36 price target suggesting limited near-term upside, making the stock a speculative hold for income-focused investors tolerant of high risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →
